| abstract |
Tumors are identified as responsive to treatment with HER dimerization inhibitors (HDIs) are identified by treating a HER expressing tumor with an HDI (which may be the same or different from that contemplated for treatment), and determining the reactivity of the tumor with the HDI. Lack of or diminished reactivity is an indication that the tumor is likely to be responsive to treatment with the dimerization ihibitor. |